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Abstract The study was designed to evaluate efficacy
and superiority of capecitabine/bevacizumab ? vinorel-
bine (CAP/BEV/VIN) compared to CAP/BEV alone. Main
purpose was to introduce a taxane-/anthracycline-free first-
line treatment in advanced breast cancer (ABC), in order to
avoid long-term toxicities. In this open-label, superiority,
phase 3 trial, patients with HER2-negative ABC were
randomized 1:1 to receive either oral CAP at 1000 mg/m2
[twice daily, days 1–14, q3w] plus intravenous BEV at
15 mg/kg [day 1, q3w] (arm A) or in addition to this
protocol intravenous VIN at 25 mg/m2 [days 1 ? 8, q3w]
(arm B) until disease progression, unacceptable toxicity or
withdrawal of consent. Between 26 February 2009 and 26
October 2012, we randomised 600 patients (arm A
N = 300; arm B N = 300) from 57 German outpatient-
centres and 2 university hospitals. Median progression-free
survival (PFS) (primary endpoint) was not improved with
VIN (CAP/BEV, 8.8 months; CAP/BEV/VIN, 9.6 months;
HR 0.84 [95 % CI 0.70–1.01], P = 0.058). Median overall
survival (OS) (secondary endpoint) was 25.1 and
27.2 months for CAP/BEV and CAP/BEV/VIN, respec-
tively, average HR 0.85 [95 % CI 0.70–1.03], P = 0.104).
The 1- and 2-year OS rates appeared to be similar (78.0 and
77.0 %; 53.0 and 54.0 %). Toxicity profiles were generally
mild and manageable. Adverse events occurred more fre-
quently in arm B. Regarding the balance between clinical
efficacy (PFS, OS) and toxicity, the CAP/BEV combina-
tion provides a favourable treatment option in first-line
ABC avoiding taxane- and/or anthracycline-induced long-
term toxicity. Superiority of CAP/BEV/VIN was not met,
and side effects were even enhanced. Nevertheless, no
safety issues occurred.
Keywords Taxane-free regimen  Capecitabine 
Bevacizumab  Vinorelbine  First line  Advanced breast
cancer
Key message
The CARIN trial is a large randomized phase 3 trial
evaluating capecitabine/bevacizumab with or without
vinorelbine in first-line treatment of ABC. PFS and OS are
encouraging in both arms. Since the triple combination did
not meet superiority, we suggest capecitabine/bevacizumab
is favourable and recommendable, as OS is encouraging
and taxane-/anthracycline-induced long-term toxicities can
be avoided.
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Introduction
Despite many new treatment options, advanced breast
cancer (ABC) remains essentially incurable. Taxanes,
especially paclitaxel (PAC), and anthracyclines represent
standard agents in first-line chemotherapy [1, 2]. Unfortu-
nately, taxanes and anthracyclines are associated with
substantial side effects, including peripheral neuropathy,
myelosuppression, cardiotoxicity, and hair loss [3, 4] that
heavily impair patients’ performance and quality of life [5,
6]. Prolonged taxane and anthracycline exposure is not
feasible because of cumulative toxic effects [7]. Therefore,
capecitabine (CAP)-based combinations provide an effec-
tive and less toxic alternative for patients without rapidly
progressive disease [8].
The addition of bevacizumab (BEV) to first-line
chemotherapy in the E2100, AVADO, and RIBBON-1
trials resulted in prolongation of progression-free survival
(PFS) and improved overall response rates (ORR) as
compared to chemotherapy alone [9–11]. The placebo-
controlled RIBBON-1 trial [11] was the first study
demonstrating significantly improved ORR and PFS by
adding BEV to first-line chemotherapy with either taxane-/
anthracycline or CAP -based treatment. The TURANDOT
trial [12, 13], a randomised phase 3 non-inferiority head-
to-head study, assessed efficacy of BEV in combination
with either PAC or CAP in first-line treatment for HER2-
negative ABC.
Recently presented final OS data indicated non-inferi-
ority of CAP/BEV (demonstrated in the stratified per-pro-
tocol analysis, supported by the stratified intent-to-treat
analysis but not in the unstratified analysis). The OS curves
seemed much the same, both in the per-protocol or the
intent-to-treat analysis [13]. Although both, the TUR-
ANDOT and RIBBON-1 trial, demonstrated improved PFS
for taxanes in combination with BEV, this did not translate
into survival benefit.
Vinorelbine (VIN) monotherapy, evaluated in several
clinical trials after failure of taxane-/anthracycline-based
first-line metastatic treatment, yielded ORRs of about 29 %
[14, 15]. VIN in combination with CAP revealed promising
clinical activity and good tolerability in the neoadjuvant as
well as in the metastatic setting [16–18]. Overlapping
toxicities of both substances were rare.
CARIN was developed to improve efficacy through
combination of VIN with CAP/BEV, thus offering an
effective taxane-/anthracycline-free treatment option in
first-line therapy of ABC. Primary objective was to
demonstrate clinical superiority of CAP/BEV/VIN com-
pared to CAP/BEV in terms of PFS. Secondary objectives
included ORR, safety, and OS.
Methods
Patients
Eligible patients had HER2/-negative measurable or non-
measurable disease, inoperable locally recurrent or ABC,
no previous chemotherapy for advanced disease, and
ECOG performance status B2; were aged C18 years; and
had no sign of brain metastases. Adjuvant chemotherapy
with either CAP or BEV or VIN was allowed if completed
at least 12 months before randomisation. Further inclusion
criteria comprised adequate liver, renal, cardiac, and
haematological function; no uncontrolled hypertension; or
proteinuria. All patients provided written informed con-
sent. Independent ethics committees at all participating
sites approved the protocol and all modifications.
Study design
CARIN was an open-label, randomised phase 3 trial. 600
patients were randomly assigned (1:1) to receive either
CAP/BEV (arm A) or CAP/BEV/VIN (arm B). Randomi-
sation was stratified by prior (neo)adjuvant therapy with
taxanes or anthracyclines (yes/no) and hormone receptor
status (±).
In both arms, CAP was administered orally at 1000 mg/
m2 (twice daily, days 1–14, q3w), combined with intra-
venous BEV at 15 mg/kg (day 1, q3w). In arm B, intra-
venous VIN was added to CAP/BEV at 25 mg/m2 (days
1 ? 8, q3w). Treatment was continued until progression of
disease (PD), unacceptable toxicity, or withdrawal of
consent. If any drug was discontinued for reasons of toxi-
city, treatment continued on the reduced regimen at allo-
cated dosages. No BEV dose reduction was permitted, but
treatment could be delayed. Beyond progression, all
patients were offered standard-of-care treatment.
Efficacy and safety assessments
Tumour assessments according to RECIST 1.0 were per-
formed at baseline, thereafter every 9 weeks until PD. After
PD, patients were followed up for survival every 3 months
over up to 3 years after last patient in.
Safety and tolerability assessments in terms of routine
laboratory parameters, urinalysis, and vital signs were
performed on a regular basis every cycle. Adverse events
(AEs) were reported systematically throughout the study,
including a 30-day safety follow-up period after treatment
discontinuation. Toxicity was graded according to the
National Cancer Institute Common Toxicity Criteria, v3.0
and classified according to MedDRA v17.0 coding.
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Statistical analysis
PFS as the primary objective was calculated from the date
of randomisation to the date of first signs of tumour pro-
gression or death from any cause. Patients not experiencing
PD or death were censored at the date of either last visit or
start of new antineoplastic treatment. Calculating a drop-
out rate of 10 %, a total of 600 patients (a = 0.05, two-
sided, power = 80 %) were to be enrolled. At study data
cut-off for analysis, less events than expected were
observed, reducing the power to detect the initially calcu-
lated PFS difference between treatment arms (8.0 vs. 10.3;
HR = 0.78) to 75 %. Secondary endpoints included ORR,
OS, and safety.
Treatment effects on PFS were calculated and compared
between treatment arms and within subgroups using the
Kaplan–Meier and Cox regression method. Hazard ratios
(HR) and 95 % confidence intervals (CI) were estimated by
Cox proportional hazards analysis. Subgroup analyses were
considered exploratory, no alpha adjustment for multiple
testing was applied to the eight comparisons of subgroups:
‘age (\65 vs. C65 years)’, ‘number of metastatic sites (\3
vs. C3 sites)’, ‘prior taxane/anthracycline (yes/no)’, ‘vis-
ceral disease (involved/not involved)’, ‘triple negative
breast cancer (TNBC yes/no)’, ‘ECOG performance status
(0 vs. 1/2)’, ‘prior palliative endocrine therapy (yes/no)’,
and ‘bone metastases (yes/no)’.
Since the OS curves for treatment comparison appeared
non-proportional, average hazard ratios were determined
by weighted Cox regression method [19]. For OS subgroup
analyses, the Cox proportional hazards were estimated.
For objective response evaluation, treatment groups
were compared using Cochran Mantel–Haenszel test.
Patients were considered evaluable for response if they had
measurable disease at baseline.
Demographic and clinical characteristics were evaluated
descriptively. All statistical analyses were performed using
Statistica v10.0 and R v3.2.0.
Results
Patients
Between 26 February 2009 and 26 October 2012, 600
patients with locally advanced disease or ABC from 59
German outpatient centres and university hospitals were
randomised, and 592 were eligible for efficacy and safety
analysis (arm A, N = 297; arm B, N = 295). Eight
patients did not receive the allocated treatment. The main
reason for treatment discontinuation was PD (arm A, 179
[60.3 %]; arm B, 137 [46.4 %]). Treatment was perma-
nently discontinued due to AE in 48 (16.1 %) and in 75
(25.4 %) patients in arms A and B, respectively (Fig. 1,
[trial profile]).
Patient demographic and clinical baseline characteristics
were generally well balanced between both arms (Table 1).
Notably, the full analysis population was characterized by a
considerable portion of patients older than 65 years
(arm A: 105 [35.4 %]; arm B 132 [44.7 %]). The majority
of patients was heavily pre-treated with (neo)adjuvant
chemotherapy (arm A: 193 [65.0 %]; arm B: 195
[66.1 %]), including 114 (38.4 %) and 95 (32.2 %) patients
with prior (neo)adjuvant taxane treatment in arm A and
arm B, respectively. The proportion of patients with TNBC
was identical in both arms (arm A: 61 [20.5 %]; arm B: 61
[20.7 %]).
Treatment exposure
Median duration of treatment was comparable between
both arms (arm A: 27.9 weeks; arm B: 29.0 weeks).
Median dose intensities for CAP were 84 and 79 % and for
BEV 98 and 94 % in arms A and B, respectively. VIN
dose intensity was 85 % (data not shown).
Efficacy
The addition of VIN slightly increased median PFS com-
pared to CAP/BEV alone (8.8 vs. 9.6 months; HR 0.84
[95 % CI 0.70–1.01], log-rank P = 0.058), and therefore,
the criteria for superiority of CAP/BEV/VIN were not met
(Fig. 2, [patient characteristics]).
Hence, potential PFS differences between treatments
were observed. When exploring subgroups according to
clinical characteristics, significantly improved PFS among
patients aged \65 years (8.2 vs. 10.2 months, HR 0.73
[95 % CI 0.58–0.93], P = 0.009), with\3 metastatic sites
(8.8 vs. 10.7 months, HR 0.74 [95 % CI 0.59–0.93],
P = 0.009), with (neo)adjuvant taxane/anthracycline pre-
treatment (7.2 vs. 9.6 months, HR 0.71 [95 % CI
0.56–0.90], P = 0.004), with non-visceral disease (9.2 vs.
12.0 months, HR 0.63 [95 % CI 0.42–0.93], P = 0.020),
with TNBC (4.2 vs. 7.0 months, HR 0.57 [95 % CI
0.39–0.84], P = 0.004), and with bone-only metastases
(12.6 vs. 15.4 months, HR 0.46 [95 % CI 0.24–0.88],
P = 0.017) was observed (Fig. 3, [subgroup analysis of
progression-free survival]).
Confirmed ORRs were significantly lower in arm A
compared to arm B (36.3 vs. 47.5 %, P = 0.047). Among
responders, median duration of response was fairly com-
parable between arm A and arm B (8.8 vs. 9.6 months, HR
0.99 [95 % CI 0.67–1.45], P = 0.944) (data not shown).
At a median follow-up of 22.2 and 23.6 months in
arm A and arm B, respectively, in total, 418 (70.6 %)
patients had died (arm A: 218 [73.4 %]; arm B: 200
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[67.8 %]) (Fig. 4). The 1- and 2-year OS rates were quite
similar between both treatment arms (arm A: 77.6 and
53.3 %; arm B: 76.6 and 54.4 %) (data not shown). Also,
median OS appeared comparable in arm A and arm B,
respectively (25.1 vs. 27.2 months; Average HR 0.85
[95 % CI 0.70–1.03], P = 0.104). Nevertheless, treatment
effects on OS became obvious comparing arm A versus
arm B, respectively, within subgroups with taxane/anthra-
cycline pre-treatment (21.5 vs. 25.2 months, HR 0.70
[95 % CI 0.54–0.90], P = 0.0048), and with non-visceral
disease (29.3 vs. 42.4 months; HR 0.64 [95 % CI
0.51–0.98], P = 0.040) (Fig. 4, [Kaplan–Meier estimate
for overall survival]).
Safety
Common grade 3/4 events were (N patients [%], arm A
vs. B) as follows: Nausea/vomiting (8 [2.7 %] vs.
19 [6.4 %]), Infection (27 [9.1 %] vs. 34 [11.5 %]), Fati-
gue/malaise (6 [2.0 %] vs. 19 [6.4 %]), Thromboembolic
events (12 [4.0 %] vs. 15 [5.1 %]) including pulmonary
embolism (4 [1.3 %] vs. 14 [4.8 %]), and peripheral neu-
ropathia (1 [0.3 %] vs. 11 [3.7 %]) (Table 2b, [adverse
events], separated by grades 3 and 4).
Conversely, grade 3/4 hand-foot syndrome was reported
more often in arm A (70 [23.6 %] vs. 43 [14.6 %]), diar-
rhoea was reported slightly more often (13 [4.3 %] vs.
9 [3.0 %]), and hypertension occurred clearly more
frequently in arm A (23 [7.8 %] vs. 9 [3.1 %]). Mucosal
inflammation was reported equally (8 [2.7 %]) in both
arms. Haematological toxicities as neutropenia (3 [1.0 %]
vs. 57 [19.3 %]), leukopenia (1 [0.3 %] vs. 31 [10.5 %]),
and febrile neutropenia (2 [0.7 %] vs. 5 [1.7 %]) were
considerably more frequently reported in arm B. Overall,
AEs of grade 3/4 (173 [58.2 %] vs. 216 [73.2 %]), serious
AEs (112 [37.7 %] vs. 146 [49.5 %]), and AEs leading to
treatment discontinuation occurred more often in arm B
(Table 2a, [Overview of safety results]). In arm A,
respectively, 63 (21.2 %) and 65 (21.9 %) patients required
BEV and CAP treatment discontinuations due to AEs. In
arm B, reflecting the higher incidence of AEs, more
patients discontinued BEV (91 [30.8 %]), CAP (89
[30.2 %]), and VIN (100 [33.9 %]) treatment.
Serious AEs, deemed to be treatment-related by the
investigator, led to death of three patients in arm A (pan-
cytopenia, thromboembolic event, pulmonary embolism),
and of two patients in arm B (pulmonary embolism and
leukopenia associated with sepsis) (data not shown).
Discussion
The CARIN trial, a German phase 3 study, aimed to
improve efficacy of CAP/BEV by adding VIN to establish
a less toxic alternative to taxane-/anthracycline-based first-
line treatment. PFS was the primary endpoint assuming a
Fig. 1 Trial profile
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difference of 2.3 months in favour of the CAP/BEV/VIN
combination. In the unselected population, superiority of
the triple combination was not met. Exploring subgroups,
the effect was more pronounced.
Compared to other phase 3 studies, the CARIN median
PFS for CAP/BEV (8.8 months) was in the range of that
observed in the CAP/BEV cohort of the TURANDOT
(8.1 months) [12, 13] and the RIBBON-1 (9.2 months)












297 60.6 (28.9–85.1) 295 62.7 (34.1–88.3) 592 61.8 (28.9–88.3)
\65 years, n | % 192 64.6 % 163 55.3 % 355 60.0 %
C65 years, n | % 105 35.4 % 132 44.7 % 237 40.0 %
Clinical characteristics
Menopausal status
Postmenopausal 243 81.8 % 241 81.7 % 484 81.8 %
ECOG performance status
ECOG 0 172 57.9 % 182 61.7 % 354 59.8 %
ECOG 1/2 105 35.4 % 94 31.9 % 199 33.6 %
Disease free interval
B12 months 23 7.7 % 18 6.1 % 41 6.9 %
[12 months 216 72.7 % 228 77.3 % 444 75.0 %
Metastatic at primary diagnosis 58 19.5 % 49 16.6 % 107 18.1 %
Measurable disease 179 60.3 % 162 54.9 % 341 57.6 %
\3 metastatic sites 206 69.4 % 202 68.5 % 408 68.9 %
C3 metastatic sites 91 30.6 % 93 31.5 % 184 31.1 %
Metastatic sites
Visceral 232 78.1 % 225 76.3 % 457 77.2 %
Liver 142 47.8 % 143 48.5 % 285 48.1 %
Lung 90 30.3 % 89 30.2 % 179 30.2 %
Bone 149 50.2 % 177 60.0 % 326 55.1 %
Bone only 26 8.8 % 34 11.5 % 60 10.1 %
Receptor status
Hormone receptor positive 236 79.5 % 233 79.0 % 469 79.2 %
HER2-negative 295 99.3 % 293 99.3 % 588 99.3 %
Triple-negative 61 20.5 % 61 20.7 % 122 20.6 %
Prior treatment for primary breast cancer 278 93.6 % 280 94.9 % 558 94.3 %
Hormone therapy 171 57.6 % 169 57.3 % 340 57.4 %
Chemotherapy 193 65.0 % 195 66.1 % 388 65.5 %
Taxanes 114 38.4 % 95 32.2 % 209 35.3 %
Anthracyclines 162 54.6 % 162 55.0 % 324 54.7 %
Prior treatment for locally recurrent or metastatic disease 128 43.1 % 148 50.2 % 276 46.6 %
Radiotherapy 92 31.0 % 96 32.5 % 188 31.8 %
Hormone therapy 109 36.7 % 118 40.0 % 227 38.3 %
ECOG Eastern Cooperative Oncology Group; HER2 human epidermal growth factor receptor 2
Arm A capecitabine/bevacizumab; Arm B capecitabine/bevacizumab/vinorelbine
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[11] trials. RIBBON-1 [11] was the first study investigating
efficacy and safety of BEV versus placebo combined with
different standard chemotherapy backbones to be chosen
by investigators before random assignment. This led to a
pronounced imbalance between the treatment arms
regarding taxane pre-treatment, with 40 % in the CAP/
BEV arm and only 15 % in the taxane/anthracycline arm,
thus hampering comparability of results. ORR and median
PFS were higher in each BEV combination. This effect was
most obvious in the CAP/BEV arm. The TURANDOT [12,
13] trial investigated in a randomised fashion whether OS
with CAP plus BEV would be non-inferior to PAC plus
BEV. Although response rates and PFS were significantly
higher for PAC-BEV, results of the final analysis did not
point to a survival benefit [13].
The debate regarding the use of taxanes and/or anthra-
cyclines in first-line treatment of ABC on OS is still
ongoing. The CARIN trial confirmed the efficacy of the
taxane-/anthracycline-free CAP/BEV combination with a
median OS of 25.1 months, which is quite comparable to
26.1 months reported from the CAP/BEV arm in the
TURANDOT trial. Differences in OS between CARIN and
TURANDOT may be explained by a significant discrep-
ancy regarding pre-treatment with adjuvant or neoadjuvant
taxanes in TURANDOT and CARIN (20 and 34 %,
respectively), pointing to a more favourable prognosis for
TURANDOT patients, when compared to the patient
population in the CARIN trial. Notably, the 1-year OS rate
in the CAP/BEV treatment arms was fairly comparable
between CARIN (78 %), TURANDOT (81 %), and RIB-
BON-1 (81 %) trials, respectively. The taxane-containing
PAC-BEV treatment in TURANDOT not only revealed OS
of 30.2 months but also enhanced peripheral neuropathy.
OS for CAP/BEV/VIN was 27.2 months.
On closer inspection, the CARIN OS estimates showed
divergent curve characteristics beyond 33 months. This
divergence may represent delayed clinical efficacy of
arm B. The divergence may also be due to the differently
responding subgroups. Particularly, subgroups with taxane/
anthracycline pre-treatment and without visceral involve-
ment obtained clinically meaningful survival benefits in the
CAP/BEV/VIN approach, confirming VIN’s therapeutic
activity. Nonetheless, these subgroup findings require fur-
ther examination in larger patient cohorts.
Regarding response induction, taxane/anthracycline-
based combinations with BEV seem to be more effective
than CAP/BEV [8, 9]. Patients presenting with life-
threatening metastatic organ involvement may thus benefit
from taxane-/anthracycline-based first-line treatment.
However, since almost all patients are at risk of devel-
oping taxane-induced neurotoxicity [21] that impairs
patients’ daily life performance and overall quality of life,
taxane treatment should be reserved for more advanced
stages.
Undoubtedly, vinca alkaloids can also induce charac-
teristic peripheral neurotoxicity [22, 23]. In this aspect,
VIN added toxicity to the CAP/BEV combination. Treat-
ment discontinuations due to toxicities occurred more fre-
quently within CAP/BEV/VIN as compared to CAP/BEV
alone, suggesting that VIN toxicities are in some way more
severe or protracted. However, in the CARIN VIN-con-
taining arm, only 10 of 295 patients developed grade 3 and
1 patient grade 4 polyneuropathy. In general, AEs[ -
grade 3 were rarely seen. Common side-effects of VIN and
main dose limiting toxicities were neutropenia, as observed
in other studies [15, 24, 25]. VIN did not cause profound
thrombocytopenia. Other toxicities were mild to moderate
and generally well manageable.
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There was an also manageable increase in adverse
events due to hand–foot syndrome. The incidence (all
grades) was higher in the CAP/BEV arm than in the CAP/
BEV/VIN arm in spite of comparable dose intensities in
both arms. In CARIN, hand–foot syndrome was mostly
responsible for discontinuations of CAP. However, as
compared to the BEV-PAC treatment arm in TURANDOT,
the proportion of treatment discontinuations due to toxic
effects in our CAP/BEV/VIN arm was somewhat lower (34
and 38 %, respectively).
The safety profile of BEV was consistent with known
side effects [26, 27] and did not lead to a significant
increase in toxicity. Severe side effects were rare even in
patients with long-term treatment.
Fig. 3 Subgroup analysis of progression-free survival according to
baseline characteristics (intent-to-treat population). HR = hazard
ratio; CI = confidence interval; ECOG = Eastern Cooperative
Oncology Group performance status; TNBC = triple-negative breast
cancer. Arm A: capecitabine/bevacizumab; arm B: capecitabine/
bevacizumab/vinorelbine
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Fig. 4 Kaplan–Meier estimate
for overall survival, separated
by pre-defined subgroups
(intent-to-treat population).
a Overall population; b taxane
and/or anthracycline pre-treated
subgroup; c non-visceral disease
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Conclusion
The CAP/BEV combination is an effective treatment
option in first-line ABC, regarding PFS (8.8 months) and
OS (25.1 months). The triple combination CAP/BEV/VIN
did not meet superiority criteria and side effects were
enhanced. The risk-/benefit-ratio were balanced in CAP/
BEV as taxane/anthracycline-induced long-term toxicities
can be avoided.
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[N = 297; n (%)]
Arm B
CAP/BEV/VIN
[N = 295; n (%)]
P value
n % n %
Any AE 286 96.3 288 97.6 0.474
Related AE (investigator assessment) 279 93.9 286 96.9 0.114
Any grade 3/4 173 58.2 216 73.2 \0.001 ***
Related grade 3/4 125 42.1 189 64.1 \0.001 ***
SAE 112 37.7 146 49.5 0.005 **
AE leading to BEV discontinuation 63 21.2 91 30.8 0.009 **
AE leading to CAP discontinuation 65 21.9 89 30.2 0.025 *
AE leading to VIN discontinuation – – 100 33.9 – –
(b) Arm A
CAP/BEV
[N = 297; n (%)]
Arm B
CAP/BEV/VIN
[N = 295; n (%)]
Grade 1/2 Grade 3 Grade 4 Grade 5 Grade 1/2 Grade 3 Grade 4 Grade 5 P value
n % n % n % n % n % n % n % n %
Hand-foot syndrome1 125 42.1 70 23.6 77 26.1 43 14.6 0.006 **
Nausea/vomiting 100 33.7 8 2.7 127 43.1 18 6.1 1 0.3 0.031 *
Infection 78 26.3 25 8.4 2 0.7 90 30.5 31 10.5 3 1.0 3 1.0 0.347 n.s.
Fatigue/malaise 83 27.9 6 2.0 106 35.9 19 6.4 0.008 **
Diarrhoea 82 27.6 12 4.0 1 0.3 1 0.3 75 25.4 8 2.7 1 0.3 1 0.3 0.516 n.s.
Hypertension 65 21.9 21 7.1 2 0.7 60 20.3 9 3.1 0.017 *
Mucosal inflammation 49 16.5 8 2.7 60 20.3 8 2.7 1.000 n.s.
Peripheral neuropathia 51 17.2 1 0.3 62 21.0 10 3.4 1 0.3 0.003 **
Haemorrhage/bleeding 39 13.1 2 0.7 1 0.3 65 22.0 2 0.7 1 0.3 1.000 n.s.
Dyspnoea 43 14.5 7 2.4 50 16.9 7 2.4 1 0.3 1.000 n.s.
Neutropenia 7 2.4 3 1.0 28 9.5 38 12.9 19 6.4 \0.001 ***
Decreased appetite 36 12.1 3 1.0 39 13.2 7 2.4 \0.001 ***
Alopecia2 20 6.7 59 20.0 0.221 n.s.
Leukopenia 5 1.7 1 0.3 17 5.8 17 5.8 14 4.7 1 0.3 \0.001 ***
General physical health
deterioration
12 4.0 8 2.7 1 0.3 1 0.3 15 5.1 10 3.4 4 1.4 0.821 n.s.
Proteinuria 20 6.7 3 1.0 18 6.1 1 0.3 0.624 n.s.
Thromboembolic event 1 0.3 12 4.0 1 0.3 10 3.4 15 5.1 0.562 n.s.
Pulmonary embolism 4 1.3 1 0.3 4 1.4 5 1.7 9 3.1 4 1.4 0.017 *
Febrile neutropenia 2 0.7 3 1.0 2 0.7 0.285 n.s.
AE adverse event; SAE serious adverse event
Arm A capecitabine/bevacizumab; Arm B capecitabine/bevacizumab/vinorelbine
1 Palmar-plantar erythrodysaesthesia syndrome; 2Alopecia only grade 1/2, grade 3/4 N/A; significance: * 0.05. ** 0.01; *** 0.001; n.s. not
significant
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